H. Lundbeck A/S

143 articles about H. Lundbeck A/S

• H. Lundbeck A/S's Alcoholism Drug Does Well in Three Phase III Clinical Studies, to File MAA by end of 2011

  6/16/2011

• BioTie Therapies Corp. and H. Lundbeck A/S Announces Positive Results from First Two Phase III Studies with Nalmefene in Alcohol Dependence

  1/3/2011

• H. Lundbeck A/S Alcoholism Pill May Be A Goldmine

  12/27/2010

• Vernalis PLC and H. Lundbeck A/S Enter into Drug Discovery Collaboration

  12/16/2010

• H. Lundbeck A/S Says Clobazam Effective In Seizures in Phase 3 Study

  12/6/2010

• H. Lundbeck A/S Braces For 2012-14 Profit Slide

  11/3/2010

• H. Lundbeck A/S Acquires Rights to Merck & Co., Inc.'s Bipolar Disorder Treatment, Syncrest

  10/12/2010

• H. Lundbeck A/S Enters Into License Agreement With Kyowa Hakko Kirin For A2a Antagonists For Parkinson's and Other Indications

  10/6/2010

• Orasi Medical Partners With H. Lundbeck A/S

  6/15/2010

• Teva Pharmaceutical Industries Limited to Market Parkinson's Drug in China for H. Lundbeck A/S

  3/1/2010

• AstraZeneca AB, Merck & Co., Inc., Novartis AG, H. Lundbeck A/S, Hoffmann-La Roche AG, And GlaxoSmithKline Explore Advances in Solubility, Amorphous Forms and Lipid-Based Formulation of Drugs

  2/4/2010

• H. Lundbeck A/S Names Sean Nolan as New CEO of its Lundbeck Inc. U.S. Subsidiary

  12/10/2009

• Forest Laboratories, Inc. and H. Lundbeck A/S Enter Into Settlement Agreement With Sun Pharmaceutical Industries Ltd and Caraco Pharmaceutical Laboratories, Ltd. Related to LEXAPRO(R) Patent Litigation

  7/10/2009

• US Panel Backs H. Lundbeck A/S Drug for Some Schizophrenics; FDA Ruling Expected by May 15

  4/8/2009

• FDA Concerned with H. Lundbeck A/S Drug Serdolect Death Risk

  4/3/2009

• H. Lundbeck A/S' Acquisition of Ovation Pharmaceuticals Cleared by US Federal Trade Commission

  3/20/2009

• GTCR Completes the Sale of Ovation Pharmaceuticals to Lundbeck Inc. (formerly Ovation Pharmaceuticals)

  3/19/2009

• Myriad Genetics, Inc. Selects H. Lundbeck A/S as European Partner for Flurizan; Myriad Receives $100 Million Upfront for European Rights to Alzheimers Disease Drug Candidate

  5/22/2008

• H. Lundbeck A/S New Data Reinforces the Superiority of Escitalopram Over Duloxetine for Acute Treatment of Depression

  12/5/2007

• H. Lundbeck A/S Newly Published Data Demonstrates Superiority of Cipralex® Over Duloxetine for Acute Treatment of Depression

  6/4/2007